Every 8-K that NextCure, Inc. (NXTC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NXTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXTC filings page.
NextCure, Inc. (NXTC) entered into a Ninth Amendment to its lease with ARE-8000/9000/10000 Virginia Manor, LLC covering approximately 29,864 rentable square feet of lab and office space in Beltsville, Maryland. The company vacated and surrendered the premises effective August 31, 2026, and the parties agreed to accelerate the lease expiration and terminate NextCure’s future rent obligations effective September 1, 2026, subject to the terms of the amendment.
In connection with this amendment, NextCure paid a one-time termination fee of approximately $0.8 million and forfeited a security deposit of approximately $39,000.
NextCure, Inc. reported second quarter 2026 results and provided a business update. For the three months ended June 30, 2026, research and development expense was $7,425 thousand versus $24,091 thousand a year earlier, general and administrative expense was $2,592 thousand versus $3,201 thousand, and the company recorded an asset impairment charge of $5,077 thousand. Net loss for the quarter was $14,892 thousand compared with $26,808 thousand in the prior-year period, or $2.80 per basic and diluted share versus $11.29, on weighted-average shares of 5,309,724 versus 2,374,729.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $20,088 thousand, down from $41,818 thousand at December 31, 2025, with total stockholders’ equity of $12,149 thousand. The company highlighted its all-stock merger agreement with Avere Therapeutics and Avere’s concurrent private financing expected to generate approximately $320 million in gross proceeds immediately prior to closing, subject to customary closing conditions. After completion, the combined company is expected to operate as Avere Therapeutics, trade on Nasdaq under the ticker AVRX, and NextCure stockholders are expected to retain an ownership interest and receive contingent value rights linked to specified legacy NextCure assets.
NextCure also outlined pipeline changes. For SIM0505, an ADC targeting CDH6, U.S. trial sites have been instructed to stop enrolling new patients while the company evaluates options to preserve asset value. For LNCB74, an ADC directed to B7-H4, partner LigaChem has elected to continue development as sole developing party under a Transition and Continuation Agreement, with NextCure remaining eligible for potential milestone and royalty payments.
NextCure, Inc. agreed to an all‑stock merger with privately held Avere Therapeutics using a two‑step subsidiary structure intended to qualify as a tax‑free reorganization. Avere shareholders and PIPE investors will receive NextCure common stock or pre‑funded warrants, subject to per‑holder beneficial ownership caps up to 19.99%.
Concurrently, institutional investors committed approximately $320 million in a private placement into Avere, conditioned on closing and at least $150,000,000 of proceeds being available to Avere at merger close. The combined company will be renamed Avere Therapeutics, is expected to trade on Nasdaq under a new ticker, and will be led by Avere’s existing management and board.
Existing NextCure stockholders will receive contingent value rights giving them 90% of gross proceeds, if any, from monetizing specified legacy assets during the CVR term. NextCure approved a restructuring that will reduce a substantial majority of its workforce and trigger about $1.9 million of charges. The company is halting further SIM0505 enrollment outside China and has opted out of cost‑sharing on LNCB74, while exploring potential partnering or sale of these programs.
NextCure, Inc. reported the results of its 2026 Annual Meeting of Stockholders and the approval of changes to its equity incentive plan. Stockholders approved an amendment and restatement of the 2019 Omnibus Incentive Plan, increasing the maximum shares of common stock authorized for issuance under the plan by 80,000 shares and updating the evergreen provision to be based on fully diluted outstanding shares, including prefunded warrants.
Two Class I directors, Anne Borgman, M.D., and John G. Houston, Ph.D., were elected to three-year terms. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 and approved, on an advisory basis, the compensation of the company’s named executive officers.
NextCure, Inc. reported Phase 1 dose escalation data for its investigational ADC SIM0505 in advanced solid tumors, with a focus on gynecologic cancers. The study enrolled 59 heavily pre-treated patients in the U.S. and China at doses from 1.6 mg/kg to 9.6 mg/kg without CDH6 preselection.
Among 20 gynecologic cancer patients in therapeutic dose cohorts of 4.8–8.0 mg/kg with at least 12 weeks of follow-up, the objective response rate was 55% (11/20). Ovarian cancer patients (n=17) had a 52.9% ORR (9/17), and uterine serous carcinoma patients (n=3) had a 66.7% ORR (2/3), based on RECIST 1.1.
In 59 patients, treatment-emergent adverse events were mainly hematologic, nausea and vomiting; grade 3–4 events were predominantly hematologic and described as manageable without primary prophylaxis. Dose discontinuations were linked to interstitial lung disease, fungal pneumonia and thrombocytopenia at higher doses. NextCure stated that its existing cash, cash equivalents and marketable securities are expected to fund planned operations into the first quarter of 2027.
NextCure, Inc. reported first quarter 2026 results and highlighted pipeline progress. The FDA granted Fast Track designation to SIM0505 for platinum-resistant ovarian cancer, and initial Phase 1 dose escalation data are expected in Q2 2026, with a planned ASCO 2026 presentation.
Management is expanding SIM0505 development by increasing U.S. trial sites and moving into Canada and Europe, while Phase 1 enrollment continues for the LNCB74 B7-H4 antibody-drug conjugate. For the quarter ended March 31, 2026, research and development expense was $6.8M and general and administrative expense was $3.3M.
Net loss was $9.8M, or $1.87 per share, compared with a $11.0M loss, or $4.70 per share, a year earlier. Cash, cash equivalents and marketable securities totaled $29.7M as of March 31, 2026.
NextCure reported full year 2025 results and highlighted progress on its antibody-drug conjugate pipeline. The company is preparing to present Phase 1 dose escalation data for SIM0505 in Q2 2026 and plans to begin enrolling platinum-resistant ovarian cancer patients into a Phase 1 dose optimization study, while doubling U.S. trial sites and expanding into additional countries.
For the year ended December 31, 2025, research and development expenses were 44,923 (in thousands) and general and administrative expenses were 12,693 (in thousands), with no restructuring and asset impairment charges compared to 2,542 (in thousands) in 2024. Net loss was 55,844 (in thousands), or 19.65 per basic and diluted share, versus 23.88 in 2024 (restated for a reverse stock split. Cash, cash equivalents, and marketable securities were 41,818 (in thousands) as of December 31, 2025, down from 68,621 (in thousands) a year earlier, and total stockholders’ equity declined to 34,943 (in thousands) from 65,472 (in thousands).
NextCure, Inc. filed a current report describing its preliminary year-end liquidity and program updates. The company announced that as of December 31, 2025, it had approximately $41.8 million in cash, cash equivalents and marketable securities, and it currently expects these resources to fund planned operating expenses and capital expenditures into the first half of 2027. This cash figure is unaudited, subject to adjustment, and will be finalized with the company’s consolidated financial statements for 2025.
NextCure also filed a press release and an updated corporate presentation as exhibits, which include updates on its two antibody drug conjugate programs. The report highlights that certain statements, including those about cash runway, development plans, clinical progress and upcoming milestones, are forward-looking and subject to significant risks and uncertainties outlined in the company’s recent annual and quarterly reports.
NextCure, Inc. entered into a securities purchase agreement for a private placement of 708,428 shares of common stock at $8.52 per share and pre-funded warrants to purchase up to 1,815,049 shares at $8.519 per warrant, raising gross proceeds of about $21.5 million before fees. The pre-funded warrants are exercisable immediately and do not expire. NextCure agreed to register the resale of the shares and warrant shares for the participating institutional and accredited investors and to temporarily restrict additional equity issuance, subject to exceptions. The company also announced that, based on its assumptions, its cash, cash equivalents and marketable securities are expected to fund planned operations into the first half of 2027.
NextCure, Inc. filed a current report stating that it released its financial results for the quarter ended September 30, 2025. On November 5, 2025, the company issued a press release with these quarterly results and attached it as Exhibit 99.1. The report clarifies that this press release is being furnished, not filed, which affects how it is treated under securities laws.
NextCure, Inc. announced that Chief Scientific Officer Solomon Langermann, Ph.D., resigned from his position effective September 1, 2025. His decision to step down is stated as not the result of any disagreement with the company’s operations, policies, or practices.
The board and company publicly thanked Dr. Langermann for his scientific leadership and many contributions during his tenure. The filing does not describe a successor or changes to the company’s scientific programs, focusing instead on the timing and amicable nature of his departure.
NextCure, Inc. (NASDAQ: NXTC) executed a 1-for-12 reverse stock split of its common shares, effective 12:01 a.m. ET on 14 July 2025, pursuant to an amendment to its Third Amended and Restated Certificate of Incorporation approved by shareholders on 20 June 2025 and subsequently adopted by the Board of Directors.
The split consolidates every twelve pre-split shares into one post-split share and proportionally adjusts outstanding equity awards: (i) shares available under the 2019 Omnibus Plan and 2019 Employee Stock Purchase Plan, (ii) annual ESPP “evergreen” additions, and (iii) option share counts, with a corresponding increase in option exercise prices. The authorised share count remains 100 million. No fractional shares will be issued; cash will be paid in lieu of fractions based on the prior trading day’s closing price. Trading on a split-adjusted basis begins 14 July 2025 under the unchanged ticker “NXTC.”